Debora Romeo Bertola

Debora Romeo Bertola

Auto-generated profile, based on publicly available information

Debora Romeo Bertola

Medical Genetics Unit, Pediatrics Department, Hospital das Clínicas da Faculdade de Medicina da Universidade de São Paulo (HC-FMUSP) , São Paulo 05403-000

Research Focus & Metrics

Academic Career Length

28Years (1999-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 June 2002 in The American Journal of Human Genetics
Verified
Journal Article
Closed access
MTMarco Tartaglia
Marco Tartaglia
KKKamini Kalidas
Kamini Kalidas
ASAdam Shaw
Adam Shaw
XSXiaoling Song
Xiaoling Song
DMDan L. Musat
Dan L. Musat
BGBruce D. Gelb
Bruce D. Gelb

13 February 2023 in American Journal of Medical Genetics Part A
Verified
Journal Article
Open access
PDF file
SUSheila Unger
Sheila Unger
CFCarlos R. Ferreira
Carlos R. Ferreira
GMGeert R. Mortier
Geert R. Mortier
HAHouda Ali
Houda Ali
DBDébora R. Bertola
Débora R. Bertola
ASAndrea Superti-Furga
Andrea Superti-Furga
The “Nosology of genetic skeletal disorders” has undergone its 11th revision and now contains 771 entries associated with 552 genes reflecting advances in molecular delineation of new disorders thanks to advances in DNA sequencing technology. The most significant change as compared to previous versions is the adoption of the dyadic naming system, systematically associating a phenotypic entity with the gene it arises from. We consider this a significant step forward as dyadic naming is more informative and less prone to errors than the traditional use of list numberings and eponyms. Despite the adoption of dyadic naming, efforts have been made to maintain strong ties to the MIM catalog and its historical data. As with the previous versions, the list of disorders and genes in the Nosology may be useful in considering the differential diagnosis in the clinic, directing bioinformatic analysis of next‐generation sequencing results, and providing a basis for novel advances in biology and medicine.

1 April 2008 in The Journal of Clinical Endocrinology & Metabolism
Verified
Journal Article
Open access
PDF file
CKChong Ae Kim
Chong Ae Kim
MDMarc Delépine
Marc Delépine
EBEmilie Boutet
Emilie Boutet
HMHaquima El Mourabit
Haquima El Mourabit
SLSoazig Le Lay
Soazig Le Lay
JMJocelyne Magré
Jocelyne Magré
Context: Berardinelli-Seip congenital lipodystrophy (BSCL) is a rare recessive disease characterized by near absence of adipose tissue, resulting in severe dyslipidemia and insulin resistance. In most reported cases, BSCL is due to alterations in either seipin, of unknown function, or 1-acylglycerol-3-phosphate acyltransferase-β (AGPAT2), which catalyzes the formation of phosphatidic acid. Objective: We sought to determine the genetic origin of the unexplained cases of BSCL. We thus sequenced CAV1, encoding caveolin-1, as a candidate gene involved in insulin signaling and lipid homeostasis. CAV1 is a key structural component of plasma membrane caveolae, and Cav1-deficient mice display progressive loss of adipose tissue and insulin resistance. Design: We undertook phenotyping studies and molecular screening of CAV1 in four patients with BSCL with no mutation in the genes encoding either seipin or AGPAT2. Results: A homozygous nonsense mutation (p.Glu38X) was identified in CAV1 in a patient with BSCL born from a consanguineous union. This mutation affects both the α- and β-CAV1 isoforms and ablates CAV1 expression in skin fibroblasts. Detailed magnetic resonance imaging of the proband confirmed near total absence of both sc and visceral adipose tissue, with only vestigial amounts in the dorsal sc regions. In keeping with the lack of adipose tissue, the proband was also severely insulin resistant and dyslipidemic. In addition, the proband had mild hypocalcemia likely due to vitamin D resistance. Conclusions: These findings identify CAV1 as a new BSCL-related gene and support a critical role for caveolins in human adipocyte function.

20 March 2015 in Journal of Medical Genetics
Verified
Journal Article
Open access
PDF file
GYGuilherme Lopes Yamamoto
Guilherme Lopes Yamamoto
MAMeire Aguena
Meire Aguena
MGMonika Gos
Monika Gos
CHChristina Hung
Christina Hung
JPJacek Pilch
Jacek Pilch
DBDébora Romeo Bertola
Débora Romeo Bertola
Background: Noonan syndrome is an autosomal dominant, multisystemic disorder caused by dysregulation of the RAS/mitogen activated protein kinase (MAPK) pathway. Heterozygous, pathogenic variants in 11 known genes account for approximately 80% of cases. The identification of novel genes associated with Noonan syndrome has become increasingly challenging, since they might be responsible for very small fractions of the cases. Methods: A cohort of 50 Brazilian probands negative for pathogenic variants in the known genes associated with Noonan syndrome was tested through whole-exome sequencing along with the relatives in the familial cases. Families from the USA and Poland with mutations in the newly identified genes were included subsequently. Results: We identified rare, segregating or de novo missense variants in SOS2 and LZTR1 in 4% and 8%, respectively, of the 50 Brazilian probands. SOS2 and LZTR1 variants were also found to segregate in one American and one Polish family. Notably, SOS2 variants were identified in patients with marked ectodermal involvement, similar to patients with SOS1 mutations. Conclusions: We identified two novel genes, SOS2 and LZTR1, associated with Noonan syndrome, thereby expanding the molecular spectrum of RASopathies. Mutations in these genes are responsible for approximately 3% of all patients with Noonan syndrome. While SOS2 is a natural candidate, because of its homology with SOS1, the functional role of LZTR1 in the RAS/MAPK pathway is not known, and it could not have been identified without the large pedigrees. Additional functional studies are needed to elucidate the role of LZTR1 in RAS/MAPK signalling and in the pathogenesis of Noonan syndrome.

1 February 2012 in The American Journal of Human Genetics
Verified
Journal Article
Closed access
RHRebecca L. Hood
Rebecca L. Hood
MLMatthew A. Lines
Matthew A. Lines
SNSarah M. Nikkel
Sarah M. Nikkel
JSJeremy Schwartzentruber
Jeremy Schwartzentruber
CBChandree Beaulieu
Chandree Beaulieu
KBKym M. Boycott
Kym M. Boycott

23 July 2014 in European Journal of Human Genetics
Verified
Journal Article
Open access
PDF file
AVAlain Verloes
Alain Verloes
NDNataliya Di Donato
Nataliya Di Donato
JMJulien Masliah-Planchon
Julien Masliah-Planchon
MJMarjolijn Jongmans
Marjolijn Jongmans
OAOmar A Abdul-Raman
Omar A Abdul-Raman
DPDaniela T Pilz
Daniela T Pilz
Baraitser–Winter, Fryns–Aftimos and cerebrofrontofacial syndrome types 1 and 3 have recently been associated with heterozygous gain-of-function mutations in one of the two ubiquitous cytoplasmic actin-encoding genes ACTB and ACTG1 that encode β- and γ-actins. We present detailed phenotypic descriptions and neuroimaging on 36 patients analyzed by our group and six cases from the literature with a molecularly proven actinopathy (9 ACTG1 and 33 ACTB). The major clinical anomalies are striking dysmorphic facial features with hypertelorism, broad nose with large tip and prominent root, congenital non-myopathic ptosis, ridged metopic suture and arched eyebrows. Iris or retinal coloboma is present in many cases, as is sensorineural deafness. Cleft lip and palate, hallux duplex, congenital heart defects and renal tract anomalies are seen in some cases. Microcephaly may develop with time. Nearly all patients with ACTG1 mutations, and around 60% of those with ACTB mutations have some degree of pachygyria with anteroposterior severity gradient, rarely lissencephaly or neuronal heterotopia. Reduction of shoulder girdle muscle bulk and progressive joint stiffness is common. Early muscular involvement, occasionally with congenital arthrogryposis, may be present. Progressive, severe dystonia was seen in one family. Intellectual disability and epilepsy are variable in severity and largely correlate with CNS anomalies. One patient developed acute lymphocytic leukemia, and another a cutaneous lymphoma, indicating that actinopathies may be cancer-predisposing disorders. Considering the multifaceted role of actins in cell physiology, we hypothesize that some clinical manifestations may be partially mutation specific. Baraitser–Winter cerebrofrontofacial syndrome is our suggested designation for this clinical entity.